Global
Corporate
Overview

Better Health, Brighter Future
Last Updated April 2024

Important notice
For the purposes of this notice, “presentation” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical
Company Limited (“Takeda”) regarding this presentation. This presentation (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent orform part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any
jurisdiction. No shares or other securities are being offered to the public by means of this presentation. No offering of securities shall be made in the United States except pursuant to registration under the U.S.
Securities Act of 1933, as amended, or an exemption therefrom. This presentation is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by
the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of
applicable securities laws.
The companies in which Takeda directly and indirectly owns investments are separate entities. In this presentation, “Takeda” is sometimes used for convenience where references are made to Takeda and its
subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by
identifying the particular company or companies.

The product names appearing in this document are trademarks or registered trademarks owned by Takeda, or their respective owners.
Forward-Looking Statements
This presentation and any materials distributed in connection with this presentation may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results ofoperations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”,“aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based onassumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic
circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations,
including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty ofcommercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or
product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on otherfacets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s);and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at:https://www.takeda.com/investors/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this presentation or any other forward-looking
statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this presentation may not be indicative of,and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

Medical information
This presentation contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths.
Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

2

“At Takeda, patients always come first.
We also believe that a focus on trust,

reputation, and business, in that order,
sets us apart”
Christophe Weber
President & CEO

SUPPORTING PATIENTSFOR 242 YEARSWho we are
Creating better health for people and a brighter

future for the world is Takeda’s purpose. The
science and technology we advance are constantly
evolving, but through our enduring values ourambition remains steadfast. We strive to deliver
truly transformative treatments, contributing

significant value to society while creating an
exceptional experience for our people.

4

Our Corporate Philosophy
PurposeBetter health for people, brighter future for the world.

VisionDiscover and deliver life-transforming treatments, guided byour commitment to patients, our people and the planet.

Values:Takeda-ism

We are guided by our values of Takeda-ism which incorporate
Integrity, Fairness, Honesty and Perseverance, with Integrityat the core. They are brought to life through actions based on
Patient-Trust-Reputation-Business, in that order.

Imperatives
PATIENT• Responsibly translatescience into highly
innovative, life-transforming
medicines and vaccines• Accelerate accessto improve lives
worldwide

PEOPLE

PLANET• Create an exceptional
people experience• Protect our planet

UNLEASH THE POWER OF DATA AND DIGITAL• We strive to transform Takeda into the most trusted, data-driven,outcomes-based biopharmaceutical company
5

A global biopharmaceutical company
FY22 REVENUEGLOBAL HEADQUARTERS

TOKYO, JAPANGLOBAL HUB

CAMBRIDGE,
MA, USA

14%

FOUNDED IN

G RO WTH &E M E RG ING
M ARK E TS

APPROX

$30.3

*

21%
E U RO PE &CANAD A

~ 30

25 +
3

NEW MOLECULAR
ENTITY CLINICAL
STAGE ASSETS

MANUFACTURINGSITESRESEARCH
SITES

200 +

PARTNERSHIPS TO HELPUS BRING INNOVATIONTO PATIENTS80

TOP EMPLOYER®
IN

39

COUNTRIES &4 REGIONSU .S.

BILLION

PR ESEN CE: APPR OX. IN

COUNTRIES& REGIONS

.

52%

1781
OSAKA, JAPAN13%
J APAN* Convenience translation of reported JPY figures into USD
at an average rate of 132.75 JPY/USD. FY2022 revenue
amount as of March 31, 2023.

15%
G RO WTH &E M E RG ING
M AR K E TS30%
E U RO PE &CANAD AALL N UM B ER S AS OF JUN E 2023

43%

APPROX.

U .S.

50,000EMPLOYEES12%J APANOURPEOPLE

Takeda Executive TeamC H RIS T O PH E WE BE R
Representative Director;
President & CEO

A K I K O A MA K A WA
Corporate Strategy
Officer, CEO Chief of Staff

A N D Y PL U MP
Director; President,
Research & Development

JULIE KIM
President,
US Business Unit

L A U RE N D U PRE Y
Chief Human Resources
OfficerT A K A K O O H Y A BU
Chief Global Corporate Affairs& Sustainability Officer

T E RE S A BIT E T T I
President, Global
Oncology Business Unit

ELAINE SHANNON
Global Quality Officer

GA BRIE L E RIC C I
Chief Data &Technology Officer

GI L E S PL A T FO RD
President, Plasma-Derived
Therapies Business Unit

MA RC E L L O A GO S T I
Global Business
Development Officer

MI L A N O FU RU T A
Chief Financial Officer

MWA N A L U GO GO
Chief Ethics &Compliance Officer

RA MO N A S E Q U E I RA
President,
Global Portfolio Division

T H O MA S WO ZN IE WS K I
Global Manufacturing &Supply Officer

Y O S H I H I RO N A K A GA WA
Global General Counsel

A S U K A MIY A BA S H I RA
President, Japan PharmaBusiness Unit

NATIONALITIES

9AGES30-60 s
WOMEN

53 %
7

How we innovate
We are building one of the most exciting anddiverse pipelines in the industry. We follow scienceand aim to unlock innovation wherever it originates– whether we are developing a therapy in one of
our laboratories or through our more than 200
partnerships. Together with our investments in data

and digital technologies, we aim to improve thepatient experience and revolutionize our approachto science.

8

We aim to discover and deliver life-transforming treatments
GASTROINTESTINAL &INFLAMMATION
•
•
•
•
•

Inflammatory Bowel disease (IBD)
Celiac disease
Dermatological & Rheumatic diseases
Liver diseases
Neurogastric disorders

RARE DISEASES
Rare Hematology and Hemostasis• Hemophilia• Von Willebrand disease• Thrombotic thrombocytopenic purpura
Rare Immunology• Hereditary Angioedema• Immune Deficiency diseases• Rare Autoimmune disorders• Hypoalbuminemia & Hypovolemia• Severe Congenital Protein C deficiency• Prothrombin deficiency• Alpha-1 Antitrypsin deficiency
Rare Metabolic• Hunter syndrome• Fabry disease• Gaucher disease• CMV & transplant

9

1 Includes Partnerships and clinical program, see current Pipeline for details.

PLASMA-DERIVED THERAPIES
•
•
•
•
•
•

Immunodeficiencies
Neuroimmunology
Hematology
Pulmonology
Specialty & critical care
Other rare & chronic diseases

ONCOLOGY• Solid tumors• Hematology

NEUROSCIENCE• Rare epilepsies• Sleep-wake disorders• Parkinson’s disease

VACCINES 1••••

DengueCOVID-19
Zika
Pandemic influenza

Research and development
SMALL
MOLECULES• BIOLOGICS

30• CELLTHERAPIESNEW MOLECULAR ENTITY
CLINICAL STAGE ASSETS• PEPTIDES & OLIGONUCLEOTIDES• OTHER MODALITIES

200 +$4.8 Bn *Robust Clinical Pipelinesof Novel Mechanisms

Diversified Modalities
in Research

Active Partnerships

R&D Investment
for FY22

Approx.

Leveraging patient insights,
matching the right target withthe right modality and executing
experiments with rigor
to accelerate therapies withtransformative potential.

More than 60% of our pipeline
is partnered, allowing us to tap
cutting-edge science andinnovation at the source.
External partnerships with startups, biotech and academia help
us bring innovative solutions topatients.

In addition to late-stage
programs with potential tolaunch multiple treatments inthe near-term, critical programsin earlier stages of development
provide sustainable long-term
opportunities to advancescientific innovation.

50%
Of pipeline with orphan drug
designation potential in at least
one indication/ in any region.

10

75%

Approx.

*Amount as of June 30, 2023. FY22 based on
exchange rate of 131 JPY to 1 USD.

Our approach to sustainability
Our sustained growth through enduring values fuses

why we exist (our purpose) with where we are going(our vision) and how we deliver on our vision (our values).
By using our core strengths and capabilities as abiopharmaceutical company, Takeda creates long-termvalue for patients, stakeholders and society while alsosustaining positive impact for our people, communities,
and the planet.

11

Our Sustainability Framework

PAT I E N T

PEOPLE

PLANET

Deliver innovative life-transforming
medicines and vaccines

Develop talent and invest
in lifelong learning

Achieve net-zero ambition

Provide health benefits that are valuedby patients and society

Advance diversity, equity and inclusion

Conserve natural resources

Accelerate global, equitable accessto medicines and vaccines

Create a culture of well-being

Design with sustainability in mind

D ATA , D I G I TA L A N D T E C H N O L O G Y E N A B L E S O U R I N N O V AT I O NS U S TA I N E D B U S I N E S S G R O W T H
12

Our efforts in data, digital and technology enable us toaccelerate innovation and provide sustained positive impact
PAT I E N T

PEOPLE

PLANET

Deliver personalized
experiences for patientsand optimized
therapeutic outcomes.

Upskill our workforce ofthe future to create aculture of digital thinking
and efficient solutions.

Improve data, enableeasier patient access, andimprove diversity withinclinical trials.

Provide a consistent,
intuitive, inclusive andcollaborative technology
experience wherever,whenever and however
our people work.

Pursue a GreenTech
strategy throughconsolidating data
centers, cloud
efficiencies, recycling
tech while sustainably
procuring new devices.

Use predictive analytics(AI and Generative AI) totarget future dengue
outbreaks, support
clinical trials and new
drug development, andstrengthen our supply
chain.
13

Design a sustainability
data collection strategy
with digital efficiencies
and automation.
Develop analytics andreporting on
environmental impact.

Access to Medicine (AtM) programs
Our AtM programs continue to positively impact the lives ofpatients, particularly those diagnosed with a serious
condition in underserved communities around the world.

Health Systems Strengthening

We are working with diverse partners in low- and middleincome countries and countries with evolving healthcare
systems to build capability in the health care system

Bridging the Affordability Gap
Takeda’s Innovative Patient Affordability and Charitable
Access Programs provide access to innovative medicines inmore than 44 countries and territories around the world.
These programs have bridged the affordability gap for
more than 5,000 patients.

Data up to March 2023

Building Trust
In 2022, we ranked in the top 10 out of the 20 largest
pharmaceutical companies evaluated by the Access to
Medicines Index (7th overall). AtM-Index rankings

LEAR N M OR E IN TH E 2022 ACCESS TO M EDICIN ES PR OG R ESS R EPOR T ON TAKEDA.COM
14

Our passion for people transforms our work
into meaningful action
We believe we can create an exceptional people experience for everyone
at Takeda by focusing on these four areas:•

Talent | Develop and attract top talent to deliver our vision with a highly
engaged workforce•

Well-being | Focus on empowering life-work alignment to enhance well-being and increase productivity.

•

Diversity, Equity & Inclusion | Drive positive change by promoting andimproving diversity, equity and inclusion•

Learning | Create an environment that fosters lifelong learning and a
growth mindset, enabling employees to thrive inside and outside of Takeda

RECOGNITION AROUND THE WORLD
Proud to be recognized around the world for our workplace environment and employee offerings.

OUR WAYS OF WORKING
We’re evolving our ways of working to build a flexible,
enriching experience that fosters our values,
promotes employee well-being and creates inclusion
with regular face-to-face interactions for specific workand collaboration.

15

Our actions to reduce our impact on the environment

Achieved and maintained
Carbon Neutrality

67% of suppliersby GHG emissions

50% of paper andpaperboard packaging

5% reduction in fresh
water withdrawal

across our value chain since 2020

will establish science-basedtargets by 2024

on secondary and tertiary level recycled
or forest stewardship certified by 2025

By 20252022

16

100% Renewable Energy

Natural Gas to Green SteamSolar Installation

Positive Energy Building

Japan

Cambridge, Massachusetts, U.S.

Los Angeles, CA., U.S.

Singapore

Our Osaka, Hikari & Narita sites areworking toward purchasing 100%
renewable electricity, which will resultin a 30% annual reduction of GHG
emissions

Conversion will reduce operational
greenhouse gas emissions by 40-50% in
two locations

Annual reduction of electricity
purchases by ca. 833 MWh andelimination of GHG emissions byapproximately 280 metric tons

First positive energy building following
the Singapore zero energy building
schemeOur actions to reduce our impact on the environment

Zero waste-to-landfill
By 2030

60% Freshwater
Consumption Reduced

Net-zero GHG emissions
from our own operations
before 2035

Waste-to-Landfill Diversion

Lessines, BelgiumFirst large-scale wastewater recycling
facility of its kind to be used in thepharmaceutical industry.

17
17

In FY2022, more than 80% of our waste
was diverted from landfills.

Net-zero GHG emissions
across our value chain
before 2040

Supplier Collaboration

Sustainability by Design

Energize Program

Lead to Industry-First Process

A first-of-its-kind initiative by 19 pharmacompanies to increase access torenewable energy sources for suppliers

Applying “Green Chemistry” Principles to
R&D process led to reducing water usage
in the manufacturing process

Our Global CSR Program and partnerships
Our Global CSR Program strives for better health for people and a brighter future for the world, where prevention
measures are exponentially advanced, the health workforce is empowered, systems are prepared against emergency
shocks, and people are freed from the burden of disease, with reliable access to quality care.
GLOBAL CSR PROGRAM (FY2016-2023)
Activities in

Selected annually

93

COUNTRIES

A total of$167.5M

BY EMPLOYEEVOTESTOTAL DONATIONAMOUNT COMMITTED

29

PROGRAMSGLOBAL CSR PARTNERSHIPSWORKING TOGETHER WITH GAME -CHANGING
MULTILATERAL AND ACADEMIC INSTITUTIONS WORLDWIDE18

L E A R N MO R E O N T A K E DA . CO M

18

Published: April 2024
Global Corporate Affairs

Takeda Global Headquarters

19

Visit us online atwww.takeda.com

Appendix

FOR SOCIETY

FOR BUSINESSOur history 1781 – 1979

21

1781

1895

1915

1943

1949

1951

COMPANY FOUNDED

PRODUCTIONOSAKA FACTORYCOMPANY NAME

Chobei Takeda I sets up his
business in Osaka

Pharmaceuticalmanufacturing begins in
Takeda’s factory

Opens as “Takeda
Pharmaceutical
Manufacturing Plant”

becomes "Takeda
Pharmaceutical
Company Limited"

INITIAL PUBLIC
OFFERING

INTERNATIONAL
BUSINESS

Takeda listed on thestock market

Starts with North andCentral America and Asia

1871

1914

1940

1946

1950s

1961

INTERNATIONAL TRADEPROPRIETARYRESEARCH“NORI” PRINCIPLESHIKARI FACTORYPANVITAN® & ALINAMIN®

COMPANY LOGO

which underpin Takeda-ism,
are established

Opens in Yamaguchi
prefecture

Japan’s ﬁrst multivitamin productand a Vitamin B1 derivative launch

The current “Dakiyama”
logo is created

1933

1960

1963

TAKEDA GARDENSHOSHISHAFOUNDATIONTAKEDA SCIENCE
FOUNDATION

is established to support
talented students who willcontribute to society

is established to encouragepromising research andscience technology

Takeda pioneers in theimportation of western medicines

activities begin

For Medicinal Plant
Conservation opens

PRESENTATION TITLEFOR SOCIETY

FOR BUSINESSOur history 1980 – present
1980s & 90s

2008

2011

2018

2019

EXPANSION OF
INTERNATIONAL
BUSINESSMILLENNIUM
PHARMACEUTICALSNYCOMED AQUISITIONNEW YORK STOCK EXCHANGE LISTINGSHIRE ACQUISITION

expands Takeda’s global
footprint into more than 70
countries worldwide

The only pharmaceutical company listed on boththe TSE and the NYSE

makes Takeda a global
biopharmaceutical leader with apresence in approximately 80
countries

accelerates with the launch ofleuprorelin, lansoprazole,candesartan, pioglitazone

acquisition enhances
innovation in oncology

SHONAN HEALTH INNOVATION PARK
opens as the first pharma-led open innovation
ecosystem in Japan

TAKEDA GLOBAL HEADQUARTERS
opens in Tokyo, providing an environment that
supports diverse workstyles

2009

2010

2016

2019

Takeda joins the

TAKEDA INITIATIVEACCESS TO MEDICINESTAKEDA INITIATIVE 2

UNITED NATIONSGLOBAL COMPACT

is formed to support thedevelopment of healthcare
professionals in Africa

program launched to improve access to care andtreatment for patients in underserved communities

launched to improve maternal andchild health by integrating quality HIV,
TB, and malaria services in Africa

GLOBAL CSR PROGRAM
launched to contribute to the better health ofpeople through disease prevention.

Corporate governance structure
Our advanced and robust corporate governance model has been,
and will continue to be, critical to our success.
GENERAL MEETING OF SHAREHOLDERSREPORTINGREPORTING/
STATEMENT
OF OPINIONAPPOINTMENT/DISMISSALAPPOINTMENT/DISMISSAL
OF MEMBERSREPORTINGAPPOINTMENT/DISMISSAL/NON REAPPOINTMENT
OF MEMBERSREPORTING

N O MI N A T I O N C O MMI T T E E
CONSULTATIONC O MPE N S A T I O N
C O MMI T T E E

REC OMMENDATION

BO A RD O F
D IRE C T O RS

AUDITINGA U D I T A N D S U PE RVI S O RY
C O MMI T T E E
REPORTING

CH AIRIN D E PE N D E NT D IRE C T O RAPPOINTMENT/DISMISSALDISCUSSION/REPORTING

SUPERVISIONINSTRUCTION

T H E GRO U P I N T E RN A L
A U D I T D E PA RT ME N T
INSTRUCTIONREPORTINGT A K E D A E X E C U T IVE T E A M ( T E T )PRE S ID E N T A N D C H IE F
E X E C U T IVE O FFIC E R ( C E O )BUSINESS & SUSTAINABILITYC O MMI T T E E

PO RT FO L IO RE VIE W
C O MMIT T E E
DISCUSSION/REPORTINGRIS K , E T H IC S &C O MPL IA N C E C O MMI T T E E

EXECUTION-RELATE D
INSTRUCTIONS/SUP ERV ISIO N

H E A D O F E A C H U N IT A N D PRE S ID E N T S O F T H E GRO U P C O MPA N I E S

23

L E A RN MO RE O N T A K E D A . C O M

ACCOUNTING AUDITORREPORTING

INTERNAL AUDITINGBoard of directors – values and corporate governanceTakeda’s Board of Directors is accountable for ensuring that all our decisions and actions are in the best interests of all stakeholders, and aligned with
our values. 12 of our 15 Board members serve as Independent External Directors, bringing further diversity and global experience to the Board.

3 INTERNAL DIRECTORS

12 INDEPENDENT EXTERNAL DIRECTORS
CB

NC

CC

CC

NC

C H RIS T O PH E WE BE R

C O S T A S A RO U K O S

Representative Director,
President & CEO

Director,
Chief Financial Officer

MA S A MI IIJ IMA
External Director,
Chair of the Board Meeting

O L I VI E R BO H U O N

J E A N - L U C BU T E L

I A N C L A RK

External Director

External Director

External Director

NC

NC

CC

24

A N D Y PL U MP

S T E VE N GIL L IS

Director, President,
Research & Development

External Director

CB

CHAIR OF THE BOARD MEETINGASC

AUDIT & SUPERVISORY COMMITTEENCNOMINATION COMMITTEE1CCCOMPENSATION COMMITTEE

1. Christophe Weber participates in the committee as an observer.

J O H N MA RA GA N O RE

MIC H E L O RS IN GE R

External Director

External DirectorASC

MIK I T S U S A K AExternal Director

ASC

ASC

NC

CC

K O J I H A T S U K A WAY O S H I A K I FU J I MO RI

External Director,
Chair of ASC

External Director

ASC

E MI K O H I GA S H I

K I MBE RL Y A . RE E DExternal Director

External Director